# PRO-232 in Patients Subjected to Cataract Surgery

> **NCT07305987** · PHASE3 · RECRUITING · sponsor: **Laboratorios Sophia S.A de C.V.** · enrollment: 134 (estimated)

## Conditions studied

- Cataract Extraction

## Interventions

- **DRUG:** Moxifloxacin / Dexamethasone Ophthalmic Solution
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin Hydrochloride, Ophthalmic
- **DRUG:** Dexamethasone phosphate

## Key facts

- **NCT ID:** NCT07305987
- **Lead sponsor:** Laboratorios Sophia S.A de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07305987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07305987, "PRO-232 in Patients Subjected to Cataract Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07305987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*